Quick Answer
Kyverna Therapeutics, Inc. reported Operating Income Loss of -$169.83 million for the year ending 2025.
- Kyverna Therapeutics, Inc. showed a decrease of -19.1% in Operating Income Loss from 2024 to 2025.
- This data is from Kyverna Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
- XBRL data for this metric is available from 2023 to 2025 (3 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2023: -$11.45 million | Q2 2023: -$13.30 million | Q3 2023: -$16.28 million | Q1 2024: -$29.36 million | Q2 2024: -$33.44 million | Q3 2024: -$38.77 million | Q1 2025: -$47.41 million | Q2 2025: -$44.41 million | Q3 2025: -$38.73 million.
- Over the full 3 years of available data (2023 to 2025), Kyverna Therapeutics, Inc.'s Operating Income Loss has declined by 172.1%.
- Historical annual values: Fiscal year 2025: -$169.83 million | Fiscal year 2024: -$142.60 million | Fiscal year 2023: -$62.41 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: